



Noxopharm Limited ([ASX:NOX](#)) | ASX Announcement | 5 January 2022

Noxopharm Announces Leadership Transition Ahead of Important Growth Phase

Sydney 5 January 2022: Australian clinical-stage drug development company Noxopharm Limited (ASX: NOX) is pleased to announce the appointment of Dr Gisela Mautner as its Chief Executive Officer from 1 February 2022, with Dr Kelly remaining on the Board as a Non-Executive Director and shifting from an executive to a consultant role. Dr Mautner, currently the Company's Chief Medical Officer, also will serve on the Board as Executive Managing Director.

Noxopharm CEO, Dr Graham Kelly, said, "The Company is in the process of transiting from an early-stage biotech company into a serious bio-pharma company looking to make its mark on the world stage. I made the decision several months ago that 2022 was the time for a generational change and time to hand over to someone with large pharma industry experience who could oversee the Company position itself as a valuable partnering opportunity. Having worked alongside Gisela for several years now, I have full confidence in her ability to achieve that objective. I believe she will make an outstanding CEO.

"As the Company's largest shareholder, ongoing Board member and Inventor of much of the Company's intellectual property, I intend to remain actively involved in the Company's future."

Noxopharm Non-Executive Chairman, Mr Fred Bart, said, "Graham has, with the full support of the Board, chosen to transition from the CEO/MD role and has accepted the Board's invitation to continue as a non-executive director and as a consultant to support Gisela as required. The Board would like to thank Graham for his unrelenting dedication and commitment to Noxopharm and welcomes his ongoing contribution. The Board regards Gisela as an outstanding successor and is confident in her ability to create and advance significant shareholder value in the years ahead."

Noxopharm CMO, Dr Mautner, said, "Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the Company through its next stages. I look forward to working with the Board and the talented team at Noxopharm to deliver success and value for our many stakeholders. A new Department Head is being appointed to oversee the delivery of our Clinical Development Program."

-ENDS-

Fred Bart, Non-Executive Chairman of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Dr Gisela Mautner Biography

Dr Mautner is a medical doctor with extensive pharmaceutical industry experience covering all aspects from clinical research through to product commercialisation. She has held senior leadership positions at MSD, Bayer and Amgen where she successfully launched several new drugs in different therapeutic areas. In her early career Dr Mautner worked as a clinical scientist at the National Institutes of Health in the USA.

She received her MD and PhD in Medicine from the two top ranking universities in Germany. Dr Mautner has a Master's degree in Public Health from Harvard University and an MBA from Northwestern University, Kellogg School of Management.

Dr Mautner is deeply engaged with the pharmaceutical community and has served on the Executive Committee of APPA (Australian Pharmaceutical Medical and Scientific Professionals Association) for numerous years. She recently handed over her Presidency of APPA and continues to serve in the role of Past President to promote excellence within the pharmaceutical community.

Dr Mautner joined Noxopharm 3 years ago and has served as the Chief Medical Officer, overseeing the implementation of the Company's clinical programs.

Summary of Material Terms of Dr Mautner's Employment

Commencement date	1st February 2022
Term	No fixed term. Ongoing until terminated by either party in accordance with the employment contract
Fixed Remuneration	Fixed Remuneration \$410,000 per annum (plus superannuation at 10%, without any contribution limited under the Superannuation Guarantee (Administration Act 1992) and subject to annual review
Performance options	Dr Mautner has been offered 2 million options at a strike price of \$0.54 that vest in 4 years subject to certain performance hurdles. These options are subject to shareholder approval to be voted on at the next shareholder meeting
Notice Period	Either party may terminate the employment by providing 3 months' notice.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome (septic shock).

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING/TBK1 signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology



treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.